 BOSTON, Dec. 14, 2020 GLOBE NEWSWIRE -- X4 Pharmaceuticals, Inc. Nasdaq: XFOR, a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the companys clinical development programs. 